Roche has signed its second molecular glue deal in a month, this time paying $50 million upfront to Monte Rosa Therapeutics for the use of its QuEEN platform to target cancer and neurological diseases previously considered out of reach.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,